Clinical trials: Depressive
Major Depressive Disorder, Insomnia
A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00435279
- Testing
- Eszopiclone, Venlafaxine
- Where
- 69 sites in Austria, Croatia and 8 more
- Volunteers
- 678 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- Trial name
- SUVN-911 (NCT03551288)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Depression, Depressive Disorder
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling…
- Trial name
- PROSPECT (NCT00380042)
- Testing
- Cortical Stimulation
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northstar Neuroscience
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Major Depressive Disorder
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and tolerability of ascending multiple oral doses of brexpiprazole as adjunctive therapy in the treatment of elderly subjects with MDD.
- Trial name
- NCT01670279
- Testing
- Brexpiprazole
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatment Resistant Depression
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant…
- Trial name
- NCT05660642
- Testing
- BPL-003
- Where
- 3 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- Beckley Psytech Limited
Depression
Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder
This study is a phase II, randomized, double-blind, multi-center, placebo-controlled, parallel-group clinical trial and 150 subjects with depressive disorder will be enrolled.
- Trial name
- NCT07018245
- Testing
- TJ0113
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
Depressive Disorder, Major
A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency
The purpose of the study is to describe the clinical outcomes (severity of depression, severity of suicidality \& frequency of suicidal thinking, suicide events) and quality of life (QoL) of participants with symptoms of major…
- Trial name
- POWER (NCT04829669)
- Sponsor
- Janssen-Cilag Ltd.
PostPartum Depression
Curio Digital Therapy for the Treatment of Post-partum Depression
Primary Objective: Evaluate the clinical effectiveness of the MamaLift Plus app compared to control (digital sham plus treatment as usual) for the management of PPD in the observed population for a period of 9 calendar weeks.
- Trial name
- SuMMER (NCT05958095)
- Testing
- MamaLift Plus
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Healthcare Innovation Technology Lab
Major Depressive Disorder and Irritability
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
The purpose of this study is to explore the effects of fixed-dosed brexpiprazole adjunctive treatment in subjects with Major Depressive Disorder with irritability
- Trial name
- NCT02212613
- Testing
- Brexpiprazole
- Where
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy…
- Trial name
- NCT02951988
- Testing
- Rapastinel
- Where
- 137 sites in United States
- Volunteers
- 1,304 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
- Trial name
- NCT00277823
- Testing
- DVS-SR 50 mg, DVS-SR 100 mg
- Where
- 25 sites in United States
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder
Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder
The purpose of this study is to validate the effectiveness of using an integrated mobile sensing platform to deliver large-scale data-driven interventions to patients with depression.
- Trial name
- NCT02499094
- Testing
- Behavioral-data driven support
- Volunteers
- 1,004 people
- Sponsor
- Ginger.io
Bipolar Depression
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as…
- Trial name
- NCT06372964
- Testing
- Lumateperone
- Where
- 68 sites in United States, Colombia and 2 more
- Volunteers
- 384 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Unipolar Depression, Treatment Resistant Depression
Home-administered tDCS for Treatment of Depression
This study will determine the safety and efficacy of home administered tDCS in adults with unipolar depression. The device used to administer tDCS will be the Soterix Medical 1X1 mini-CT.
- Trial name
- NCT04781127
- Testing
- Soterix Medical mini-CT tDCS stimulator
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Soterix Medical
Depression, Postpartum, Postpartum Depression
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression, Post-partum Depression, Postnatal Depression
- Trial name
- NuMom (NCT06285916)
- Testing
- NORA520 Dose 1, NORA520 Dose 2
- Where
- 18 sites in United States
- Volunteers
- 93 people
- Sponsor
- TWi Biotechnology, Inc.
Major Depressive Disorder
A Study of LY2216684 and Theophylline in Healthy Subjects
The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme.
- Trial name
- NCT01263106
- Testing
- LY2216684, Theophylline
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major, Diabetic Neuropathies
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects.
- Conditions
- Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms
- Trial name
- NCT00456898
- Testing
- desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
The primary objective of the study is to compare, after 8 weeks, the efficacy of SR58611A vs. placebo in patients with Major Depressive Disorder who are on concomitant treatment with escitalopram.
- Trial name
- ALBERIO (NCT00432614)
- Testing
- SR58611A, escitalopram
- Where
- 13 sites in Belgium, Estonia and 11 more
- Volunteers
- 510 people
- Sponsor
- Sanofi